Collectively, our findings demonstrated glycoprotein PTGDS as a novel target for DLBCL treatment and highlighted the potency of AT56 as a promising therapeutic strategy for DLBCL. The gene discussed is PTGDS; the disease is diffuse large B-cell lymphoma.